Sangamo picks Lilly and PTC as buyers in bankruptcy auction Aug 12, 2026 04:01PM
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones Aug 12, 2026 04:01PM
Sangamo files Chapter 11, agrees to sell assets to Lilly, Astellas Jun 23, 2026 08:05AM
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas Jun 23, 2026 08:05AM
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results May 14, 2026 04:01PM


Mar 30, 2026 04:01PM Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
Nov 6, 2025 08:01AM Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Sep 4, 2025 08:05AM Sangamo presents data on Fabry disease gene therapy ahead of FDA filing
Sep 4, 2025 08:05AM Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
Aug 7, 2025 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
May 12, 2025 06:26PM Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Mar 17, 2025 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Dec 30, 2024 04:17PM Sangamo Therapeutics (SGMO) to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
Dec 30, 2024 04:15PM Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
Nov 12, 2024 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Aug 6, 2024 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
May 9, 2024 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Mar 13, 2024 08:05AM Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Mar 13, 2024 08:01AM Sangamo Therapeutics (SGMO) Announces Data From AAV Capsid
Mar 13, 2024 08:01AM Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Oct 3, 2011 03:05PM Unusual 11 Mid-Day Movers 10/03: (EK) (PPDI) (ACUR) Higher; (AMR) (SGMO) (DHT) Lower
Oct 3, 2011 11:02AM Morning Movers 10/03: (EK) (PPDI) (MDCO) (WGO) Higher; (SGMO) (VHC) (CAST) Lower
Oct 3, 2011 09:28AM Pre-Open Movers 10/03: (EK) (PPDI) (YHOO) Higher; (SGMO) (ACI) (VTSS) Lower (more...)